AIM: Expression of mitogen-activated protein kinase (MAPK) signaling and its role in cell proliferation of the bone malignancies, osteosarcoma (OS) and malignant fibrous histiocytoma (MFH) were investigated. MATERIALS AND METHODS: Gene expression and protein levels of RAF1 and MEK1/2 in 6 human sarcoma cell lines and 7 surgically obtained OS specimens were assessed by RT-PCR and immunohistochemistry, respectively. MEK inhibitor, U0126 [1,4-diamino-2,3-dicyano-1,4-bis (2-aminophynyltio) butadiene], was used for cell proliferation assays. RESULTS: RAF1 and MEK 1/2 mRNA was detected in all cell lines and OS specimens. RAF1, MEK 1/2 and p-MEK protein was also expressed in the cells, as was MEK1/2 in OS specimens. Treatment with U0126 resulted in dose- and time-dependent inhibition of cell proliferation and suppression of p-ERK expression, opposite to promotion of p-MEK. CONCLUSION: U0126 blocks MAPK signaling and decreases cell proliferation in OS and MFH. Thus, selective MAPK inhibitors might be therapeutically advantageous in the treatment of bone and soft tissue sarcomas.
AIM: Expression of mitogen-activated protein kinase (MAPK) signaling and its role in cell proliferation of the bone malignancies, osteosarcoma (OS) and malignant fibrous histiocytoma (MFH) were investigated. MATERIALS AND METHODS: Gene expression and protein levels of RAF1 and MEK1/2 in 6 humansarcoma cell lines and 7 surgically obtained OS specimens were assessed by RT-PCR and immunohistochemistry, respectively. MEK inhibitor, U0126 [1,4-diamino-2,3-dicyano-1,4-bis (2-aminophynyltio) butadiene], was used for cell proliferation assays. RESULTS:RAF1 and MEK 1/2 mRNA was detected in all cell lines and OS specimens. RAF1, MEK 1/2 and p-MEK protein was also expressed in the cells, as was MEK1/2 in OS specimens. Treatment with U0126 resulted in dose- and time-dependent inhibition of cell proliferation and suppression of p-ERK expression, opposite to promotion of p-MEK. CONCLUSION:U0126 blocks MAPK signaling and decreases cell proliferation in OS and MFH. Thus, selective MAPK inhibitors might be therapeutically advantageous in the treatment of bone and soft tissue sarcomas.
Authors: T S Karin Eisinger-Mathason; Vera Mucaj; Kevin M Biju; Michael S Nakazawa; Mercy Gohil; Timothy P Cash; Sam S Yoon; Nicolas Skuli; Kyung Min Park; Sharon Gerecht; M Celeste Simon Journal: Proc Natl Acad Sci U S A Date: 2015-06-15 Impact factor: 11.205
Authors: Ling Ren; Arnulfo Mendoza; Jack Zhu; Joseph W Briggs; Charles Halsey; Ellen S Hong; Sandra S Burkett; James Morrow; Michael M Lizardo; Tanasa Osborne; Samuel Q Li; Hue H Luu; Paul Meltzer; Chand Khanna Journal: Oncotarget Date: 2015-10-06